The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000436370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/03/2026
Date registered
Help: Date registered
9/04/2026
Date last updated
Help: Date last updated
9/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Experimental N. gonorrhoeae infection of the oropharynx in healthy adults with the novel strain AUSMDU00053933
Scientific title
Experimental N. gonorrhoeae infection of the oropharynx in healthy adults with the novel strain AUSMDU00053933
Additional trial identifiers [1] 316388 0
CT34087
Universal Trial Number (UTN)
Trial acronym
CURE-NG
Related trial records

Health condition
Health condition(s) studied:
Gonorrhoea 340483 0
Condition category
Condition code
Infection 336690 336690 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Experimental oropharyngeal challenge model with Neisseria gonorrhoeae strain AUSMDU00053933.
The intervention product is a strain that is in current circulation, that has been manufactured into dose vials for this trial in Melbourne, Australia. Inoculation will take place at the clinical trial site, Doherty Clinical Trials, in Melbourne.
Participants will be infected with gonorrhoea strain AUSMDU00053933 via direct swab application to the throat. As this intervention is only administered once, at the clinical trial site, adherence to intervention does not need assessment.
The participants will then be monitored daily, in-person by clinical staff during the experimental infection period (until confirmed positive gonorrhoea infection or 5 days maximum post-inoculation) for their safety and to assess for symptoms of gonorrhoea. At the end of the experimental infection period participants will be treated with antibiotics to clear any gonorrhoea infection. Antimicrobial therapy will comprise of single-dose intramuscular ceftriaxone 1000mg in 3.5mL of 1% lignocaine, and does not change based on the infection dose.
Following treatment, participants will continue to be monitored over several months via on-site follow-up visits (1, 3, 7 and 14 days following treatment, and 30 and 90 days post-inoculation) to confirm treatment success and ensure that there are no long-term effects from the infection or treatment.
A continual reassessment method (CRM) will be used to identify the AUSMDU00053933 dose that can establish oropharyngeal N. gonorrhoeae infection in 60-80% of participants. The CRM dictates that the model is updated after each cohort of five participants completes challenge, and subsequent dose allocation is informed by the model estimate. Up to five dose levels are manufactured for possible use in the trial (10^4 ± 0.5log10 CFU/ml to 10^8 ± 0.5log10 CFU/ml).
Intervention code [1] 333055 0
Other interventions
Description of the comparator or control
N/A - No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344201 0
To define the safety and tolerability of oropharyngeal inoculation of healthy volunteers with AUSMDU00053933 N. gonorrhoeae. This will be assessed as a composite primary outcome.
Timepoint [1] 344201 0
Inoculation (Day 0) to End of Study (Day 90). Adverse events may be self reported at any time during this period, and adverse events will also be assessed at each scheduled study visit and at any unscheduled contact with the study team. Clinical exams/symptom checks will take place daily between Inoculation and Treatment (approximately Day 5), and then 1, 3, 7 and 14 days post-treatment, and finally on Day 30 and 90. Safety blood tests will be taken during Screening (prior to inoculation) and then again on the Day of Treatment.
Primary outcome [2] 344202 0
To establish the dose of AUSMDU00053933 N. gonorrhoeae required to cause reproducible oropharyngeal infection rate of 60-80% within 5 days.
Timepoint [2] 344202 0
Daily from Inoculation (Day 0) to Day 5
Secondary outcome [1] 457044 0
Identifying the proportion of participants at each dose level who develop symptomatic microbiologically-confirmed gonorrhoea pharyngitis (defined as sore throat and examination score >/=2 or grade 3 pharyngitis.
Timepoint [1] 457044 0
Daily from Inoculation (Day 0) to Day 5
Secondary outcome [2] 457046 0
To identify the occurrence of severe, complicated or disseminated gonococcal infection among participants. This will be assessed as a composite secondary outcome.
Timepoint [2] 457046 0
Inoculation (Day 0) to End of Study (Day 90). Participants will be monitored for severe, complicated or disseminated gonococcal infection throughout this period, with targeted clinical examination at all scheduled study visits and at any unscheduled contact with the study team. Clinical exams/symptom checks will take place daily between Inoculation and Treatment (approximately Day 5), and then 1, 3, 7 and 14 days post-treatment, and finally on Day 30 and 90. Microbiological assessment of extra-oropharyngeal sites will be performed at baseline (pre-challenge) in all participants to exclude pre-existing infection. For participants with confirmed oropharyngeal gonorrhoea after challenge, additional testing of extra-oropharyngeal sites (e.g. rectal swab and urine sample) will be performed on the day of treatment and approximately 7 and 14 days after treatment.
Secondary outcome [3] 457047 0
Detection of N. gonorrhoeae from other susceptible mucosal sites (rectal swab and first pass urine) during the study period. This will be assessed as a composite secondary outcome.
Timepoint [3] 457047 0
Inoculation (Day 0) to End of Study (D90). Participants will be monitored for infection at other mucosal sites throughout this period, with symptom-directed clinical examination at all scheduled study visits and at any unscheduled contact with the study team. Clinical exams/symptom checks will take place daily between Inoculation and Treatment (approximately Day 5), and then 1, 3, 7 and 14 days post-treatment, and finally on Day 30 and 90. Microbiological assessment of extra-oropharyngeal mucosal sites will be performed at baseline (pre-challenge) in all participants to exclude pre-existing infection. For participants with confirmed oropharyngeal gonorrhoea after challenge, additional testing of extra-oropharyngeal sites (e.g. rectal swab and urine sample) will be performed on the day of treatment and approximately 7 and 14 days after treatment.

Eligibility
Key inclusion criteria
1. Male (assigned at birth) aged 18 to 50 years old on the day of informed consent
2. Identifies as a person who has sex with people assigned male at birth and has not had sex with individuals assigned female at birth within the previous 12 months
3. Proficient in English language
4. Total body weight >/=50kg, and a body mass index (BMI) within the range of 18 to 30 kg/m2
5. Able and willing to comply with all study requirements
6. Able to read and understand the participant information, and provide written informed consent to participate in the trial and demonstrate understanding of the study requirements by passing a quiz.
7. Provide written agreement (in the PICF) to comply with infection control guidelines during the experimental gonococcal infection phase until the study team advise that N. gonorrhoeae challenge strain eradication has been confirmed
8. Able and willing to abstain from the use of mouthwash from the day of screening until the end of study
Minimum age
18 Years
Maximum age
50 Years
Sex
Males
Healthy volunteers
Yes
Key exclusion criteria
1. History of any clinically important cardiac, endocrinologic, haematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal or other major disease, as determined by the Investigator
2. History of cancer (except adequately treated squamous cell or basal cell carcinoma of the skin more than 5 years prior)
3. History of hospitalization for illness within the six months prior to enrolment into study or major surgery within the 12 months prior to enrolment into study
4. Presence of implants or prosthesis (e.g. artificial joints, pacemakers)
5. Any clinically significant disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy
6. History of tonsillectomy or adenoidectomy
7. Any known or suspected immunodeficiencies or impairment/alteration of immune function including:
• Congenital or acquired immunodeficiency including complement deficiency, antibody deficiency, chronic granulomatous disease, HIV infection or asplenism
• Receipt of any immunosuppressive therapy such as anti-cancer chemotherapy or radiotherapy within the preceding 12 months
• Any known or suspected autoimmune disorders (mild autoimmune disorders, such as eczema, are not exclusionary and will be determined by the Investigator)
8. Use of any systemic immunomodulatory treatment including eculizumab, corticosteroids (topical corticosteroids acceptable), anti-inflammatories (beside sporadic use of non-steroidal anti-inflammatory drugs), anticoagulants (aspirin acceptable), investigational products, interleukins, interferons or growth factors within the previous three months, or anticipated use of such drugs during the study period.
9. Use of inhaled or intranasal corticosteroid from 14 days prior to challenge until 28 days after inoculation, or confirmation of N. gonorrhoeae challenge strain eradication, whichever is later
10. Use of non-prescription drugs and herbal supplements (such as St John’s Wort) within 14 days or 5 half-lives (whichever is the longer) prior to inoculation. Use of vitamin supplements taken at standard doses is allowed.
11. Known hypersensitivity or other contraindications to the use of cephalosporins, carbapenems or macrolides (including treatment with other medications that are contraindicated with ceftriaxone, azithromycin, and ertapenem and these antimicrobials and cannot be safely withheld), or anaphylaxis to penicillins.
12. Known hypersensitivity to soya protein
13. History of severe infectious disease including i) requirement for hospitalization for intravenous antibiotics; ii) prior N. meningitidis infection such as meningococcal meningitis or meningococcal bacteraemia; iii) ocular or disseminated gonococcal infection (DGI)
14. Significant acute or chronic infection within 14 days prior to inoculation that the Investigator deems may compromise participant safety
15. A history of confirmed N. gonorrhoeae infection at any other site (urogenital, anorectal or oropharyngeal) in the three months prior to challenge, including at screening or pre-enrolment testing
16. Any use of gonococcal-active antimicrobial therapy in the three months prior to challenge (including cephalosporins, carbapenems or macrolides)
17. Prior history of Neisseria meningitidis serogroup B (e.g. 4CMenB) vaccination at any time
18. Any vaccination within the 28 days prior to challenge
19. History or presence of current alcohol abuse (defined as regular alcohol consumption of more than 40g per day), illicit drug use, or any prior intravenous usage of an illicit substance
20. A current active smoker defined as having smoked a cigarette or cigar in the four weeks prior to challenge, or an ex-smoker with a more than 10 pack year smoking history
21. Occupational, household or intimate contact with immunocompromised individuals (including HIV infection, asplenia, malignancy, recurrent, severe infections and chronic immunosuppressant medication within the past 6 months)
22. Occupational or household contact with individuals below 18 years of age
23. Residence in unstable or emergency housing
24. Any employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members defined as spouse, parent, sibling or child whether biologic or legally adopted
25. Participation in another research study involving an investigational product or other intervention within 12 weeks prior to enrolment, at any time during the study and up to 12 weeks after completion of the study
26. Participation in a research study that involves blood sampling of more than 450ml/unit of blood, received or donated blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within three months before study, plans for donation at any time during the study and up to three months after the last blood test
27. Intolerance of throat swab procedure (exaggerated gag reflex)
28. Any clinically significant abnormal finding on laboratory screening investigations, with specific exclusion criteria including:
• Serum creatinine level above 1.1x upper limit of normal (ULN) and deemed clinically significant by the Investigator or delegated study clinician
• Serum ALT level above 1.25x ULN and deemed clinically significant by the Investigator or delegated study clinician
• White blood count (WBC) below 2.5 or above 15.0 x 109/L and deemed clinically significant by the study Investigator or delegated study clinician
• Haemoglobin level below 11.0 g/dl or above ULN and deemed clinically significant by the study Investigator or delegated study clinician
• C3 or C4 level below LLN or complement function test outside normal limits
• Positive serologic results for human immunodeficiency (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies and positive PCR if Hepatitis C virus antibodies detected, syphilis serology (with evidence of active untreated infection as determined by the Investigator or delegated study clinician)
• A positive urine drug test at screening or pre-enrolment (e.g. amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates) unless there is an explanation acceptable to the Investigator (e.g. the participant has stated in advance that they consumed a prescription or over the counter product which contained the detected drug) and the participant has a negative urine drug screen on repeat testing
• A positive alcohol breath test at screening or pre-inoculation visits
29. Detection of N. meningitidis on oropharyngeal swab at screening or pre-enrolment testing
30. Any other significant disease or disorder, which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the results of the study, or the participant’s ability to participate in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Single intervention (AUSMDU00053933), however, up to 5 different dose levels may be used.
A continual reassessment method (CRM) will be used to identify the AUSMDU00053933 dose that can establish oropharyngeal N. gonorrhoeae infection in 60-80% of participants. The CRM dictates that the model is updated after each cohort of five participants completes challenge, and subsequent dose allocation is informed by the model estimate.
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321001 0
Government body
Name [1] 321001 0
Medical Research Future Fund (MRFF) - Department of Health, Disability and Ageing
Country [1] 321001 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 323701 0
None
Name [1] 323701 0
Address [1] 323701 0
Country [1] 323701 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319533 0
Bellberry Human Research Ethics Committee J
Ethics committee address [1] 319533 0
Ethics committee country [1] 319533 0
Australia
Date submitted for ethics approval [1] 319533 0
29/10/2025
Approval date [1] 319533 0
14/01/2026
Ethics approval number [1] 319533 0
2025-10-1783

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147634 0
Prof James McCarthy
Address 147634 0
The University of Melbourne, Grattan Street, Parkville, Victoria, 3010
Country 147634 0
Australia
Phone 147634 0
+61 3 8344 0927
Fax 147634 0
Email 147634 0
Contact person for public queries
Name 147635 0
James McCarthy
Address 147635 0
The University of Melbourne, Grattan Street, Parkville, Victoria, 3010
Country 147635 0
Australia
Phone 147635 0
+61 3 8344 0927
Fax 147635 0
Email 147635 0
Contact person for scientific queries
Name 147636 0
James McCarthy
Address 147636 0
The University of Melbourne, Grattan Street, Parkville, Victoria, 3010
Country 147636 0
Australia
Phone 147636 0
+61 3 8344 0927
Fax 147636 0
Email 147636 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Future research related to this study

When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: CI Prof James McCarthy - [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: All requests for individual participant data will be assessed on a case-by-case basis. Depending on the nature of the request, additional considerations (for example, further ethical review, specific data use agreements, or enhanced privacy protections) may be required. We reserve the right to decline requests or to apply extra conditions where necessary.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.